Shanxi JINXIN DOUBLE-CRANE Pharmaceutical Co., Ltd.
-
Founded in:
2001-12-14 -
Country:
China -
Address:
Sanlidun, North of Xia County, Yuncheng City, Shanxi Province -
Tax NO.:
911408287281430205 -
Registered Funds:
164.191 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Siegesbeckia sibiricum (roasted with honey wine) |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| Arisaema cum bile |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| Pinellia ternata (processed) |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| Angelica (wine) |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| gastrodia tuber |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| RADIX GENTIANAE DAHURICAE |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| Riligustilide |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
89354-45-0 | 0 | |
| NOTOGINSENG RADIX ET RHIZOMA |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| PERSICAE SEMEN |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| MYLABRIS |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| CARTHAMI FLOS |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 | ||
| Borneol |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
507-70-0 | 1 | |
| artificial moschus |
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability.
More
The results of preclinical animal tests indicate that this product has a significant inhibitory effect on experimental in vivo and in vitro thrombosis in rats, and has a protective effect on focal cerebral ischemic injury in rats; it can inhibit ADP-induced platelet aggregation, reduce blood viscosity in rats with blood stasis, and improve red blood cell deformability. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Atractylodis Macrocephalae Rhizoma |
Strengthen the spleen and eliminate dampness, warm the middle and stop diarrhea
More
Strengthen the spleen and eliminate dampness, warm the middle and stop diarrhea |
0 | ||
| Bao Jiang extract |
Strengthen the spleen and eliminate dampness, warm the middle and stop diarrhea
More
Strengthen the spleen and eliminate dampness, warm the middle and stop diarrhea |
0 | ||
| HERBA PLANTAGINIS |
Strengthen the spleen and eliminate dampness, warm the middle and stop diarrhea
More
Strengthen the spleen and eliminate dampness, warm the middle and stop diarrhea |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 1-(2,6-Dichlorophenyl)-2-indolinone |
Diclofenac is a non-steroidal anti-inflammatory analgesic derived from phenylacetic acid. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby blocking the conversion of arachidonic acid into prostaglandins. At the same time, it can also promote the combination of arachidonic acid with triglycerides (triacylglycerols), reduce the concentration of free arachidonic acid in cells, and indirectly inhibit the synthesis of leukotrienes. Diclofenac is a stronger non-steroidal anti-inflammatory drug, and its inhibitory effect on prostaglandin synthesis is stronger than that of aspirin and indomethacin.
More
Diclofenac is a non-steroidal anti-inflammatory analgesic derived from phenylacetic acid. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby blocking the conversion of arachidonic acid into prostaglandins. At the same time, it can also promote the combination of arachidonic acid with triglycerides (triacylglycerols), reduce the concentration of free arachidonic acid in cells, and indirectly inhibit the synthesis of leukotrienes. Diclofenac is a stronger non-steroidal anti-inflammatory drug, and its inhibitory effect on prostaglandin synthesis is stronger than that of aspirin and indomethacin. |
15307-86-5 | 4 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| NOTOGINSENG RADIX ET RHIZOMA |
|
0 | ||
| Riligustilide |
|
89354-45-0 | 0 | |
| CARTHAMI FLOS |
|
0 | ||
| Puerariae Lobatae Radix |
|
0 | ||
| Hawthorn (pitted) |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Vitamin K1 |
This product is a vitamin drug. Vitamin K is a necessary substance for the liver to synthesize factors II, VII, IX, and X. Vitamin K deficiency can cause synthesis disorders or abnormalities of these coagulation factors, and clinically bleeding tendency and prolonged prothrombin time can be seen.
More
This product is a vitamin drug. Vitamin K is a necessary substance for the liver to synthesize factors II, VII, IX, and X. Vitamin K deficiency can cause synthesis disorders or abnormalities of these coagulation factors, and clinically bleeding tendency and prolonged prothrombin time can be seen. |
84-80-0 | 27 |